Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Denmark

European Innovation Council · Running

CancERVacc Targeting Cancer with ERV Vaccines

Coordinator
Inprother Aps, Denmark
Runs
1 July 2022 to 31 October 2025
Status
Running
EU funding
€2.5m
Total cost
€12.2m
Partners
1 organisations in 1 countries
Type
European Innovation Council
Grant agreement
190120397

What the project is doing

In the project's own words, from its summary on CORDIS.

InProTher (IPT) is developing a unique immunotherapy BreakImmune that effectively targets endogenous retroviruses (HERVs) to treat cancer. HERVs are not expressed in normal tissues, but are expressed in several major cancers, such as breast (88%), prostate (90%), ovarian (90%), and pancreatic (80%). Thus, HERVs can be a potential target for the immune system to destroy tumor cells. IPT technology relies on the engineering of HERVK antigens to be used as effective cancer vaccines.

The administration of BreakImmune, the mutated HERVK in Ad19/MVA viral vectors, induces both strong antibody and T-cell immune responses able to destroy cancer cells in multiple cancer types. Our first product is IPT001, a first in class vaccine against solid cancers in combination with checkpoint inhibitors.

Topics

Who is involved

OrganisationCityCountryRole
Inprother ApsKbenhavn NDenmarkCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI